Clinical Trial Update: An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis [Phase 4]

View source ↗

Summary

Open-label, single-arm longitudinal Phase 4 trial investigating dupilumab for atopic dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Eric Simpson | Conditions: Atopic Dermatitis, AD | Phase 4 | Status: UNKNOWN